• Explore /
  • Poster
  • / Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.

Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.

Abstract Poster

Authors

null

Yi Zhang

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Yi Zhang , Hu Zhou , Zhi-Jian Xiao , Minghui Duan , Sujun Gao , Guangsheng He , Hongmei Jing , Junmin Li , Liangming Ma , Huanling Zhu , Chunkang Chang , Xin Du , Mei Hong , Xin Li , Qingchi Liu , Wei Wang , Na Xu , Haiping Yang , Qingwei Zhao , Jie Jin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT04217993

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7061)

DOI

10.1200/JCO.2023.41.16_suppl.7061

Abstract #

7061

Poster Bd #

191

Abstract Disclosures

Similar Posters

First Author: Yi Zhang

First Author: Ruben A. Mesa

First Author: Aaron Thomas Gerds

First Author: Aaron Thomas Gerds